Literature DB >> 1864288

Evaluation of quinolones in experimental animal models of infections.

W M Scheld1.   

Abstract

Many discriminative experimental animal models of infection have been utilized in the evaluation of newer fluoroquinolones. In vivo efficacy of many of the newer agents has been shown in experimental models of meningitis, endocarditis, pneumonia, urinary tract infections, pyelonephritis, osteomyelitis, abscesses of various types, septic arthritis, gastroenteritis, salmonellosis, listeriosis, tuberculosis, syphilis, sinusitis, prostatitis and burn wound sepsis, among others. This review focuses on recent developments in a few selected areas. Although the limitations of animal model studies are well described, these results provide a rationale for the appropriate clinical usage of the newer fluoroquinolones in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864288     DOI: 10.1007/bf01967001

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  78 in total

1.  Pseudomonas immune globulin therapy improves survival in experimental Pseudomonas aeruginosa bacteremic pneumonia.

Authors:  M S Collins; A Edwards; R E Roby; N S Mehton; D Ladehoff
Journal:  Antibiot Chemother (1971)       Date:  1989

2.  Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.

Authors:  N K Henry; M S Rouse; A L Whitesell; M E McConnell; W R Wilson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

3.  Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  M T Hessen; P G Pitsakis; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.

Authors:  M Asahara; A Tsuji; S Goto; K Masuda; A Kiuchi
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams; L Morrison
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients.

Authors:  C Martin; F Gouin; F Fourrier; W Junginger; B L Prieur
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

7.  Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.

Authors:  B Kemmerich; K Borner; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 8.  Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.

Authors:  A S Bayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

9.  Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus.

Authors:  C W Norden; E Shinners; K Niederriter
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

10.  Oral ciprofloxacin for osteomyelitis.

Authors:  R R MacGregor; A L Graziani; J L Esterhai
Journal:  Orthopedics       Date:  1990-01       Impact factor: 1.390

View more
  2 in total

1.  Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.

Authors:  P Aviles; C Falcoz; R San Roman; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.

Authors:  Marc Pfister; Liping Zhang; Margareta Hammarlund-Udenaes; Lewis B Sheiner; Cynthia M Gerber; Martin G Täuber; Philippe Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.